1h Free Analyst Time
Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Immunology, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Acute Ischemic Stroke, Acute Lung Injury, Cognitive Disorders, Dilated Cardiomyopathy, Epithelial Ovarian Cancer, Facioscapulohumeral Muscular Dystrophy (FSHD), Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Ischemic Stroke, Lewy Body Dementia, Melanoma, Multiple Sclerosis, Neuropathic Pain (Neuralgia), Pain, Peritoneal Cancer, Pervasive Developmental Disorder (PDD), Post-Operative Pain, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis and Unspecified.
The latest report Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
EIP Pharma LLC
Eli Lilly and Co
Fulcrum Therapeutics Inc
GEn1E Lifesciences Inc
Ionis Pharmaceuticals Inc
Neurokine Therapeutics
Pfizer Inc
Strekin AG
Synovo GmbH
TopiVert Ltd
Zocere Inc
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Drug Profiles
Antisense Oligonucleotides to Inhibit MAPK14 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
losmapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MW-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
neflamapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit MAPK14 and MAPK11 for Multiple Sclerosis, Pancreatic Cancer Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexmetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06802861 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ralimetinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit MAPK14 for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAPK14 for Acute Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Dormant Products
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Discontinued Products
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: EIP Pharma announces presentation of phase 2b clinical trial results of neflamapimod in early-stage alzheimer's disease at clinical trials in alzheimer's disease (CTAD) meeting
Nov 08, 2019: EIP Pharma reports mixed results from neflamapimod Alzheimer’s trial
Nov 07, 2019: EIP Pharma announces U.S. FDA grants Fast-Track Designation to Neflamapimod as a treatment for Dementia with Lewy Bodies (DLB)
Oct 31, 2019: Fulcrum Therapeutics to host key opinion leader breakfast symposium on Facioscapulohumeral Dystrophy
Oct 04, 2019: Fulcrum Therapeutics announced results of phase 1 clinical trial of Losmapimod in FSHD
Oct 01, 2019: Fulcrum Therapeutics announces multiple presentations of Losmapimod Data at World Muscle Society Meeting
Sep 04, 2019: Fulcrum Therapeutics appoints Pamela Strode, Seasoned Industry Executive, to lead regulatory affairs team
Aug 21, 2019: Fulcrum launches Phase IIb trial of losmapimod to treat FSHD
Aug 19, 2019: Fulcrum Therapeutics announces initiation of ReDUX4, a phase 2b clinical trial of Losmapimod for FSHD
Jul 17, 2019: EIP Pharma announces presentation of preclinical data demonstrating effects of p38a Kinase Inhibitor Neflamapimod on the neurodegenerative process
Jul 12, 2019: EIP Pharma initiates new study with Neflamapimod for the treatment of cognitive deficits in patients with dementia with lewy bodies
Jul 10, 2019: EIP Pharma trials neflamapimod to treat cognitive deficits
Jul 08, 2019: EIP Pharma appoints Noel Donnelly as CFO
May 15, 2019: Eli Lilly presents update on phase Ib/II study of ralimetinib at ASCO 2019
Dec 13, 2018: EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by EIP Pharma LLC, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Fulcrum Therapeutics Inc, H2 2019
Pipeline by GEn1E Lifesciences Inc, H2 2019
Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Pipeline by Neurokine Therapeutics, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Strekin AG, H2 2019
Pipeline by Synovo GmbH, H2 2019
Pipeline by TopiVert Ltd, H2 2019
Pipeline by Zocere Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- EIP Pharma LLC
- Eli Lilly and Co
- Fulcrum Therapeutics Inc
- GEn1E Lifesciences Inc
- Ionis Pharmaceuticals Inc
- Neurokine Therapeutics
- Pfizer Inc
- Strekin AG
- Synovo GmbH
- TopiVert Ltd
- Zocere Inc
